DalCor Pharmaceuticals US, LLC filed a Form D with the Securities and Exchange Commission on 2026-08-28.
DalCor Pharmaceuticals US, LLC filed a Form D notice of an exempt securities offering with the SEC on August 28, 2026. The filing reports $6.96M sold. Its industry group is Pharmaceuticals. It names Douglas Dixon (Director), Paul Fonteyne (Director) (SEC Form D, August 28, 2026).
125 companies raised this week.
Companies that just raised money, and the people to call. Before you unlock: the company, the amount, the date and what is inside (for example 2 people, phone, LinkedIn). After: the officers and directors the filing names with their roles, how to reach the company, and a person's email only when we found one.
| Andersen Aggregator LLC | $1.9B | Business services |
| AT Umbrella LLC | $1.9B | Business services |
| Legora, Inc. | $221M | AI and software |
| MD INVESTMENT LLC | $169M | Business services |
| Serval Inc. | $149M | AI and software |
Selling to DalCor Pharmaceuticals US, LLC? See who runs it and how to reach them, plus this week's 25 other newly funded companies.
Is this your company?
Sell to companies like DalCor Pharmaceuticals US, LLC? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2026-08-28 · the record
Pitching, partnering or investing alongside them? See who really runs and owns DalCor Pharmaceuticals US, LLC.
Free to see. No signup.
More on the people and the money behind DalCor Pharmaceuticals US, LLC, from the filings we hold.
Pharmaceuticals raises by companies based in Florida, filed within 90 days of this one, largest first.
Get an email when DalCor Pharmaceuticals US, LLC files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when DalCor Pharmaceuticals US, LLC raises, hires or launches. No email unless you switch it on.
Watch DalCor Pharmaceuticals US, LLC →Get the full cited report on DalCor Pharmaceuticals US, LLC
What the filing shows about DalCor Pharmaceuticals US, LLC
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on DalCor Pharmaceuticals US, LLC: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives DalCor Pharmaceuticals US, LLC's address as 677 North Washington Blvd, Suite 132, Sarasota, FL 34236.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on DalCor Pharmaceuticals US, LLC See pricing
DalCor Pharmaceuticals US, LLC is a registered filer with the SEC (CIK 1673368) and has filed since 2026-08-28. 1 filing is on record, the latest on 2026-08-28.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
DalCor Pharmaceuticals US, LLC's Form D of 2026-08-28 names Douglas Dixon and Paul Fonteyne as its officers, directors or promoters.
Its new offerings report $6.96M sold across 1 offering, as its own filings state.
Trailing twelve months. 157 filings in Pharmaceuticals, totalled by week. The dot is this raise, $6.96M, on the same scale — one filing against the whole group's total, so it sits low by construction.
Douglas Dixon is named as Director on the Form D that DalCor Pharmaceuticals US, LLC filed with the SEC on 28 August 2026, one of 2 people that filing names.
Paul Fonteyne is named as Director on the Form D that DalCor Pharmaceuticals US, LLC filed with the SEC on 28 August 2026, one of 2 people that filing names.
2 people named on the filing — 2 as directors only.
Named as of the 2026-08-28 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
What the filing shows about DalCor Pharmaceuticals US, LLC
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on DalCor Pharmaceuticals US, LLC: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on DalCor Pharmaceuticals US, LLC covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist DalCor Pharmaceuticals US, LLCYou get an alert in MentionFox the next time this company shows up.
If you're behind DalCor Pharmaceuticals US, LLC: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for DalCor Pharmaceuticals US, LLC. With no account yet, you sign up free and land on the result.
On these lists: Pharmaceuticals raises in Orlando and Tampa
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/dalcor-pharmaceuticals-us-llc-form-d-26000001